Krebs board approves merger with Ipca Labs; share swap 7 Ipca shares per 200 Krebs shares
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.4 pts less than Nifty Microcap 250 and 8.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved scheme of amalgamation of Krebs Biochemicals with Ipca Laboratories under Sections 230-232 of the Companies Act, 2013. Appointed date is April 1, 2026. No cash consideration; share swap ratio is 7 fully paid Ipca equity shares (Re.1 each) for every 200 fully paid Krebs shares (Rs.10 each). Ipca FY26 total income was Rs.7,431 Cr while Krebs FY26 income was Rs.26 Cr, mostly from conversion charges from Ipca. Both are in pharma manufacturing. Rationale includes operational synergies and Krebs bringing fermentation based API capability that Ipca lacks. Treated as related party transaction at arms length. Subject to NCLT, SEBI and other approvals.
Krebs shareholders receive 7 Ipca shares per 200 held; deal secures API supply for Ipca and likely lifts Krebs stock on merger arbitrage.